This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Women's Health  • Pregnancy and Breast Feeding  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2004;292:322.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Food and Drug Administration (FDA) is cautioning breastfeeding women not to use an unapproved drug, domperidone, which may increase the secretion of prolactin and therefore increase milk production. Several published reports and case studies have linked domperidone to cardiac arrhythmias, cardiac arrest, and sudden death in patients receiving an intravenous form of the drug.

More than 2000 reports of adverse effects from 33 countries have been related to domperidone, and the drug has been withdrawn from marketing in a number of countries. Several nations, including Canada, have approved oral domperidone for gastric disorders, as it increases contractions of the stomach and bowel.

But domperidone is not approved in any country for enhancing breast milk production. It is not known if domperidone causes adverse effects in newborns, and drug labels on the oral form of the drug note that it is excreted in the milk of lactating . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?